Sign in
CompletedNo phase

Tiara™ Transcatheter Mitral Valve Replacement Study

Key facts

Who runs it
Shockwave Medical, Inc.
Where
Germany, Israel, Italy, Netherlands, Spain, and United Kingdom20 sites in 6 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
157 people enrolled
Started
8 Mar 2017
Ended
6 Aug 2024
Type of study
Interventional
Treatments tested
  • TIARA valve and transapical delivery system
Record updated
29 September 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Severe mitral regurgitation
  • High surgical risk for open mitral valve surgery
  • Subject meets anatomical eligibility criteria

Who cannot take part

  • Previous cardiac procedures: any mitral valve replacement surgery and cardiac transplant
  • Unsuitable cardiac structure
  • Clinically significant untreated Coronary Artery Disease (CAD)
  • Documented bleeding or coagulation disorders
  • Active infections requiring antibiotic therapy
  • Deemed too frail by objective frailty assessments
  • Subjects on chronic dialysis
  • Pregnant or planning pregnancy within next 12 months
  • Subjects with a life expectancy less than 12 months

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the safety and performance of the Neovasc Tiara Mitral Transcatheter Heart Valve with the Tiara Transapical Delivery System.

The group in the trial

  • TreatmentTreatment being tested

    Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system

    Treatment: TIARA valve and transapical delivery system

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Tiara™ Transcatheter Mitral Valve Replacement Study (TIARA-II)
Record updated
29 September 2025